|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0025266,
umls-concept:C0032952,
umls-concept:C0036525,
umls-concept:C0246415,
umls-concept:C0282460,
umls-concept:C0376358,
umls-concept:C0585333,
umls-concept:C0678009,
umls-concept:C1257890,
umls-concept:C1521801,
umls-concept:C1522484
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-8-12
|
|
pubmed:abstractText |
To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1464-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
5
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
551-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18510661-Aged,
pubmed-meshheading:18510661-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18510661-Disease Progression,
pubmed-meshheading:18510661-Humans,
pubmed-meshheading:18510661-Male,
pubmed-meshheading:18510661-Middle Aged,
pubmed-meshheading:18510661-Mitoxantrone,
pubmed-meshheading:18510661-Neoplasm Metastasis,
pubmed-meshheading:18510661-Neoplasms, Hormone-Dependent,
pubmed-meshheading:18510661-Pain,
pubmed-meshheading:18510661-Prednisone,
pubmed-meshheading:18510661-Prostate-Specific Antigen,
pubmed-meshheading:18510661-Prostatic Neoplasms,
pubmed-meshheading:18510661-Quality of Life,
pubmed-meshheading:18510661-Survival Analysis,
pubmed-meshheading:18510661-Taxoids,
pubmed-meshheading:18510661-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
|
|
pubmed:affiliation |
University of Montreal Hospital Centre, Montreal, PQ, Canada. fred.saad.chum@ssss.gouv.qc.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
